Vol. 11 | No.
3 |1058 - 1066 | July - September | 2018
ISSN: 0974-1496 | e-ISSN: 0976-0083 | CODEN: RJCABP
[Link]
[Link]
CONCURRENT ESTIMATION OF SOFOSBUVIR AND
VELPATASVIR IN RAW AND TABLETS USING STABILITY
INDICATING RP-HPLC METHOD
J. Saroja1, P.V. Anantha Lakshmi2,*, Y. Rammohan1, D. Divya1,
and P. Santhosh Kumar1
1
Department of Chemistry, CMR College of Engineering & Technology,
Hyderabad - 501401, India.
2
Department of Chemistry, University College of Technology, Osmania University,
Hyderabad – 500007, India.
*
E-mail: [Link]@[Link]
ABSTRACT
A stability indicating RP-HPLC method is developed and evaluated to quantify sofosbuvir and velpatasvir in raw
and tablets forms. The method involves separation and analysis of sofosbuvir, velpatasvir and their stress degradants
using Spursil C18 (250 × 4.5 mm and i.d., 5 µm particle size) analytical column with a mixture of potassium
dihydrogen phosphate (0.1 M) and methanol (pH 4.5, 60:40 v/v) as the mobile phase. The analysis was done using a
photodiode array detector at 240 nm. Calibration curves showed linearity in concentration range 10–30 (velpatasvir)
and 40–120 µg/mL (sofosbuvir). Good linearity (R2 ≥ 0.9998), good precision (RSD ≤ 0.138%, n = 5) and good
accuracy (% recovery ̴100%) for velpatasvir and sofosbuvir were achieved. Stress degradation studies were
performed on powdered tablet sample in athe cidic, basic, oxidative, thermal and photolytic atmosphere. The method
showed no interference from the degradation products formed by applied stress conditions. Application of the
proposed method to the commercially available tablets was carried out successfully. The performance of the
proposed method was compared with those from previously published HPLC methods and they were satisfactory.
Key words: hepatitis C virus, sofosbuvir, velpatasvir, stability indicating, analysis, tablets
© RASĀYAN. All rights reserved
INTRODUCTION
Hepatitis C is a chronic infection by hepatitis C virus with nearly 130-150 million of the population
infected globally1,2. Hepatitis C virus is a single-stranded ribonucleic acid virus belonging to the family
Flaviviridae. The most important objective of hepatitis C virus therapy is to obtain a sustained virological
response, resulting in complete eradication of Hepatitis C viral RNA levels, within 24 weeks following
completion of treatment3. A tablet dosage combination of velpatasvir and sofosbuvir was approved in
June 2016 by the United States Food and Drug Administration in treating hepatitis C virus-infected
patients4,5.
Sofosbuvir (a phosphoramidate prodrug) undergoes extensive intracellular metabolism to form deoxy-α-
fluoro-β-C-methyluridine triphosphate (active antiviral agent). This active antiviral agent is a defective
substrate for non-structural protein 5B which is required for transcription of viral RNA6. Velpatasvir
inhibits hepatitis C virus non-structural protein 5A and possesses potent antiviral activity against all
genotypes. Non-structural protein 5A is required for viral replication7. The chemical structures of the
sofosbuvir and velpatasvir are given in Fig. -1 and -2.
The sofosbuvir and velpatasvir combination is not yet official in pharmacopoeia. Two articles on the
concurrent estimation of sofosbuvir & velpatasvir in tablet dosage were recently reported by Sarath &
Rao and Uppalapati & Parimi8,9.
Rasayan J. Chem., 11(3), 1058-1066(2018)
[Link]
Vol. 11 | No. 3 |1058 - 1066 | July - September | 2018
In Sarath & Rao method, separation and analysis were done using Discovery® C18 column with
orthophosphoric acid plus acetonitrile (60:40 v/v) at a flow rate of 1.0 mL/min8 as mobile phase. UV
detection was performed at 240 nm. Uppalapati & Parimi achieved separation using mobile phase having
0.1% trifluoro acetic acid: methanol (42:58 vol/vol) on an XTerra RP18 column9. 1.0 mL/min is the flow
rate and 269 nm is used for detecting analytes.
Present work describes validated rapid, precise, accurate stability indicating RP-HPLC method in the
quantitation of sofosbuvir & velpatasvir combination in raw and tablets.
Fig. -1: Chemical Name and Structure of Sofosbuvir
Fig.-2: Chemical Name and Structure of Velpatasvir
EXPERIMENTAL
Instrumentation
HPLC system (Waters) with binary HPLC pump (model number 2695), PDA detector (model number
2998) and degasser with 10 µL injection loop were used. The chromatographic data was processed by
Waters Empower2 software. Electronic balance ELB 300 and Digisun pH meter were used.
Materials
Lara Drugs Private Limited (Hyderabad, Telangana, India) was kind enough in providing sofosbuvir and
velpatasvir reference substances. Sovihep V tablets having 400 mg of sofosbuvir & 100 mg of velpatasvir
(Zydus Heptiza, Ahmedabad, India) were obtained from commercial sources. Methanol of HPLC grade
was acquired from Merck Pvt Ltd. (Mumbai, Maharashtra, India). Potassium dihydrogen phosphate,
orthophosphoric acid, hydrochloric acid, hydrogen peroxide and sodium hydroxide of analytical reagent
1059
CONCURRENT ESTIMATION OF SOFOSBUVIR J. Saroja et al.
Vol. 11 | No. 3 |1058 - 1066 | July - September | 2018
grade were acquired from Sd Fine Chemicals Ltd. (Mumbai, Maharashtra, India). Water purified via
Milli-Q system was used in the study.
Chromatographic Conditions
The chromatographic separation and analysis of selected drug combination were worked out on a Spursil
C18 (250 × 4.5 mm, i.d., 5 µm particle size). The mobile phase used is a mixture of 10-1 M potassium
dihydrogen phosphate & and methanol (pH 4.5, 60:40 v/v). 1 mL/min is the flow rate. Mobile phase
filtration using 0.45 µm membrane filter was done and 10 min sonication was performed. The column
temperature is 25±2 oC while analyzing. The analyte elution was monitored using a photodiode array
detector set at 240 nm. 10 µL is the injection volume.
Solutions of Stock Standard and Tablet Sample
The stock solution was prepared by weighing 400 mg sofosbuvir & 100 mg velpatasvir, and dissolved in
30 mL of mobile phase in a volumetric flask having 100 ml capacity. A concentration of 4000 µg/mL and
1000 µg/mL of sofosbuvir and velpatasvir was achieved by the mobile phase to the final volume of the
volumetric flask. The prepared solution was further diluted using mobile phase to attain working
standards having concentration 10, 15, 20, 25 & 30 µg per mL for velpatasvir and 40, 60, 80, 100 & 120
µg per mL for sofosbuvir.
Ten tablets of Sovihep V (400 mg sofosbuvir and 100 mg velpatasvir /tablet) were powdered. Tablet
powder equal to 400 mg sofosbuvir & 100 mg velpatasvir is accurately weighed into a volumetric flask
having 100 ml capacity and mixed with 30 milli liters mobile phase. Sonication of solution performed for
20 minutes and filled by mobile phase for obtaining a final concentration of 1000 µg/mL velpatasvir and
4000 µg/mL sofosbuvir. Filtration of the solution was through 0.45 µm membrane. For analyzing the
analytes, the above-prepared tablet sample solution was diluted further to reach a concentration of 80
µg/mL and 20 µg/mL sofosbuvir and velpatasvir, respectively with the mobile phase.
Degradation Study
In this study, acidic, basic, oxidative, thermal, and photolytic degradation of tablet solution (20 µg/mL
velpatasvir & 80 µg/mL sofosbuvir) were studied10. Acid and base degradation studies were performed
using tablet powder equivalent to 400 mg sofosbuvir and 100 mg velpatasvir in HCl (0.1 N, 10 mL) and
NaOH (0.1 N, 10 mL), respectively and sonicated at room temperature for 30 min. For oxidative
degradation, the same concentration of tablet sample was used in 30% hydrogen peroxide (10 mL)
followed by sonication at room temperature for 30 min. Thermal and photolytic degradation studies were
performed on tablet powder (equivalent to 400 mg sofosbuvir and 100 mg velpatasvir). The tablet powder
was exposed to 105 oC for 30 min in oven (thermal degradation) or to sun light for 1 day (photolytic
degradation). After degrading, tablet solution was prepared as explained in “stock standard and tablet
sample solutions” section.
After the application of stress on the tablet sample, the stressed samples dilution was done by mobile
phase to a concentration of 20 µg per mL velpatasvir & 80 µg per mL sofosbuvir for analysis. The
degraded samples are filtered and then injected into the HPLC system. Calculation of peak area for
velpatasvir & sofosbuvir were noted from the respective chromatogram. Working standard solution at the
same concentration level was used to calculate the percentage of the drug remained in each degradation
condition. The peak purity of velpatasvir and sofosbuvir was also determined in all the degradation
conditions.
RESULTS AND DISCUSSION
Method Optimization
Parameters of chromatography parameters – a time of retention, peak tailing, theoretical plates count, and
resolution were determined to optimize the method. For that, trials are carried out - different mobile phase
ratios and different stationary phase types, with temperature difference, values of pH and flow rate. On
this basis method is employed to separate velpatasvir and sofosbuvir from themselves and also from stress
degradants, Spursil C18 (250 × 4.6 mm, 5 µm) column having temperature 25±2 oC was selected which
gave good symmetric and sharp peaks. Based on less analysis time, peak response, peak symmetry and
1060
CONCURRENT ESTIMATION OF SOFOSBUVIR J. Saroja et al.
Vol. 11 | No. 3 |1058 - 1066 | July - September | 2018
column efficiency, a mixture of methanol and 10-1 M potassium dihydrogen orthophosphate and methanol
(40:60 v/v) was selected as mobile phase with adjustment pH to 4.5 units and 1.0 millilitre/minute flow
rate, using photodiode array detector, a wavelength of 240 nm was selected as detection wavelength. The
chromatographic parameters optimized exhibit a good peak shape, resolution and a good number of
theoretical plates. The typical chromatogram of velpatasvir and sofosbuvir by the developed method is
presented in Fig. -3.
Fig.-2: Typical Chromatogram of Velpatasvir and Sofosbuvir by the Developed Method
Method Validation
Validation was performed by referring ICH guidelines11. HPLC Suitability, linearity, selectivity,
accuracy, sensitivity, precision, specificity and robustness were determined.
System Suitability Study
System suitability established by five consecutive injections with the same working standard solutions.
Parameters considered were: USP plate count, USP tailing, USP resolution, peak areas’ and retention
times’ relative standard deviation of velpatasvir and sofosbuvir. The values for the system suitability
parameters of the method, as presented in Table- 1, are within acceptance limits.
Table-1: System suitability parameters for velpatasvir and sofosbuvir
Retention Peak Plate Tailing
Sample Name. Resolution
time Area count factor
Velpatasvir (20 µg/mL)
A 3.089 2443324 17609 1.16 -
B 3.088 2446997 17643 1.13 -
C 3.090 2431515 17668 1.13 -
D 3.088 2446115 17338 1.13 -
E 3.090 2426416 17340 1.14 -
Average 3.089 2438873 17520 1.138 -
RSD 0.032 0.382 0.949 1.146 -
Recommended
RSD ≤ 2 RSD ≤ 2 > 2000 ≤2 -
limit
Sofosbuvir (80 µg/mL)
A 4.061 5979429 16412 1.2 8.66
B 4.059 5943909 16363 1.2 8.59
1061
CONCURRENT ESTIMATION OF SOFOSBUVIR J. Saroja et al.
Vol. 11 | No. 3 |1058 - 1066 | July - September | 2018
C 4.061 5962666 16396 1.2 8.59
D 4.061 5930444 16458 1.2 8.59
E 4.062 5947656 16444 1.21 8.58
Average 4.061 5952821 16415 1.202 8.602
RSD 0.027 0.316 0.231 0.372 0.380
Recommended
RSD ≤ 2 RSD ≤ 2 > 2000 ≤2 > 1.5
limit
Selectivity
The selectivity of the optimized HPLC method was examined with standard working solution of
velpatasvir (20 µg per mL) & sofosbuvir (80 µg per mL) relative to the placebo blank, blank mobile
phase and tablet sample solution (velpatasvir -21 µg/mL and sofosbuvir -80 µg/mL) (Fig. -4). No
interference was observed by coelution of the excipients in placebo blank, components of the mobile
phase at the same retention time of velpatasvir and sofosbuvir at 240 nm, demonstrating the selectivity of
this method. The time of velpatasvir & sofosbuvir retention in working solution and tablet solution are
alike.
Fig.-4: Chromatograms of Selectivity Study
Linearity and Sensitivity
Linearity was done by preparing standard solutions of velpatasvir and sofosbuvir at five concentration
levels. The linearity of detector response for velpatasvir and sofosbuvir was verified by prepared solutions
in concentration range 10-30 and 40-120 µg per mL, respectively. Peak area of each sample against
respective concentration of analytes was found to be linear. Correlation coefficient of velpatasvir &
sofosbuvir are 0.9998 & 0.9999. Linearity results were presented in Table-2.
1062
CONCURRENT ESTIMATION OF SOFOSBUVIR J. Saroja et al.
Vol. 11 | No. 3 |1058 - 1066 | July - September | 2018
This method’s sensitivity was represented as limits of quantification (LOQ) and detection (LOD).
Determining detection and quantitation limits is based on the signal-to-noise ratio with 3:1 & 10:1.
Determined LOD values and LOQ values for velpatasvir and sofosbuvir were shown in Table-2.
Table-2: Regression Analysis and Sensitivity of Velpatasvir and Sofosbuvir
Parameter Velpatasvir Sofosbuvir
Linearity (µg/mL) 10-30 40-120
Equation of regression
y = 12198 x - 2111 y = 74403 x + 1087
(A= SC + I)
Slope (S) 12198 74403
Intercept on Y-axis (I) -2111 1087
Regression coefficient (R2) 0.9998 0.9999
LOD (µg/mL) 0.186 0.428
LOQ (µg/mL) 0.620 1.609
A = Peak area of analyte; I = analytes’ concentration (µg/mL)
Precision and Accuracy
For precision studies, the same standard solutions of velpatasvir and sofosbuvir were injected 6 times into
the HPLC system on the same day. The percentage RSD values calculated for peak areas of velpatasvir
and sofosbuvir were less than 0.2 % (Table-3) indicating the precise assay with the developed HPLC
method. For accuracy, the percentage recovery was calculated for both active ingredients. The results
(Table-3) are acceptable with good percent recovery.
Table-3: Precision and Accuracy Evaluation for the Developed Method
Injection Velpatasvir (40 µg/mL) Sofosbuvir (80 µg/mL)
Name. Area of peak Recover % Area of peak Recover %
A 2432746 99.35 5953930 99.72
B 2438324 99.58 5954860 99.73
C 2438753 99.6 5957679 99.78
D 2431867 99.31 5956388 99.76
E 2433053 99.36 5956731 99.77
F 2438217 99.57 5955089 99.74
Mean 2436043 99.48 5956149 99.76
RSD 0.136 0.138 0.020 0.201
Recovery Test
Further evaluation of the accuracy of the method was carried through recovery test. Recovery test was
determined by means of the standard addition method. The recovery experiments were performed by
adding velpatasvir and sofosbuvir standards at three concentration levels to the placebo for three times.
The recovery test results are summarized in Table 4. Hence, the obtained results indicated that the
developed HPLC method was accurate enough for simultaneous quantitative evaluation of aspirin and
pravastatin. There was no interference noticed from the common excipients of the tablet.
Table-4: Recovery of Velpatasvir and Sofosbuvir by the Developed Method
Concentration Concentration
(µg/mL) (µg/mL) Average
Recover % Average % Recover %
%
added found added found
Velpatasvir Sofosbuvir
9.90 9.95 100.48 40.00 39.92 99.81
9.90 9.96 100.65 100.40 40.00 39.80 99.50 99.63
9.90 9.91 100.06 40.00 39.83 99.58
19.80 19.90 100.51 80.00 79.73 99.67
100.36 99.71
19.80 19.85 100.25 80.00 79.81 99.76
1063
CONCURRENT ESTIMATION OF SOFOSBUVIR J. Saroja et al.
Vol. 11 | No. 3 |1058 - 1066 | July - September | 2018
19.80 19.86 100.30 80.00 79.76 99.70
29.70 29.83 100.45 120.00 119.61 99.68
29.70 29.87 100.58 100.47 120.00 119.64 99.70 99.68
29.70 29.81 100.38 120.00 119.60 99.67
Robustness
Under the slightly varied chromatographic conditions (mobile phase’s flow rate -±0.1 mL/min &
temperature in the column - ±2 oC), velpatasvir and sofosbuvir peaks were well separated and there was
no significant change in the system suitability parameters (Table-5), which illustrated the robustness of
the method.
Table-5: System Suitability Values for Velpatasvir and Sofosbuvir under Slightly Varied Chromatographic
Conditions
Tailing in
Investigated factors Values Plate Count Resolution
peak
Velpatasvir (40 µg/mL)
1.0 - 0.1 21895 1.14 -
Flow rate (mL/min)
1.0 + 0.1 19510 1.16 -
25 - 2 20992 1.18 -
Temperature (oC)
25 + 2 20742 1.16 -
Sofosbuvir (80 µg/mL)
1.0 - 0.1 17480 1.20 9.23
Flow rate (mL/min)
1.0 + 0.1 15889 1.19 8.92
25 - 2 16511 1.20 8.91
Temperature (oC)
25 + 2 16891 1.20 9.06
Degradation Studies
Solutions of velpatasvir and sofosbuvir tablet are stressed under acidic, oxidative, alkali, thermal &
photolytic conditions. Method’s ability of stability indication and specificity are tested pertaining to the
above-said conditions. Results of degradation studies are provided in Table-6. Degraded sample’s
chromatograms shown in Fig. -5. The degradation percentage was estimated from the peak area obtained
in degradation conditions and it was compared with the assay of the nondegraded condition.
Both the drugs were degraded in all the stress conditions applied. In the entire degradation conditions, one
degradant peak is observed. From the results, it was observed that the velpatasvir is degraded more in
thermal & less in oxidative degradations. Sofosbuvir degradation is more in acid condition but less in
thermal degradation. The peak purity profile of velpatasvir and sofosbuvir was determined. The less value
of purity angle than purity threshold value showed that velpatasvir & sofosbuvir peaks are homogeneous
in every condition of degradation. Method’s nature of stability indication & specificity is demonstrated
because degradation products of applied stress have no any effect on the detection and quantitation of
velpatasvir and sofosbuvir.
Comparison of the Proposed Method with Reported Methods
Two HPLC methods are done on simultaneous evaluation of velpatasvir & sofosbuvir in tablet forms8,9.
Performance of reported and proposed HPLC methods is summarized in Table-7. From the values in the
Table-7, it was observed that the proposed method have advantages of being more quick, precise &
accurate than the reported HPLC methods. The less runtime in the proposed method not only reduces the
single analysis time but also decreases the utilization of solvents. Thus the proposed method is
economical than the reported HPLC methods. Both the reported methods were not fully validated. The
LOD and LOQ are not presented in the Sarath & Rao6 method. The specificity and selectivity are not
reported in Uppalapati & Parimi7 method.
1064
CONCURRENT ESTIMATION OF SOFOSBUVIR J. Saroja et al.
Vol. 11 | No. 3 |1058 - 1066 | July - September | 2018
Fig.- 4: Chromatograms of stress testing
Table-6: Stress Testing of Velpatasvir and Sofosbuvir
Recover Purity
Degrading type Area of peak Degraded %
% Angle Threshold
Velpatasvir (40 µg/mL)
Acid 2282112 93.20 6.80 0.420 0.908
Base 2297127 93.81 6.19 0.321 0.826
Oxidative 2304684 94.12 5.88 0.283 0.892
Heat 2272016 92.79 7.21 0.377 0.912
Sunlight 2295250 93.73 6.27 0.386 0.924
Sofosbuvir (80 µg/mL)
Acid 5526135 92.55 7.45 0.354 0.525
Base 5543131 92.84 7.16 0.231 0.425
Oxidative 5529439 92.61 7.39 0.323 0.528
Heat 5585557 93.55 6.45 0.205 0.432
Sunlight 5568801 93.27 6.73 0.299 0.443
CONCLUSION
In this study, an RP-HPLC method which is stability indicating was optimized and validated for
determining velpatasvir & sofosbuvir in raw and tablets. The method was rapid, cost-effective, accurate &
1065
CONCURRENT ESTIMATION OF SOFOSBUVIR J. Saroja et al.
Vol. 11 | No. 3 |1058 - 1066 | July - September | 2018
precise with good selectivity and specificity. Results of this method validation showed that the method
was satisfactory and so this method can be applicable in regular quality control laboratories.
Table-7: Comparison of the Proposed Method with Reported HPLC Method
Run
Flow rate Range LoD LoQ RSD
Drug time Recover % Reference
(mL/min) µg/mL µg/mL µg/mL %
(min)
25.293- 0.13- 99.98-
Vel NR NR
252.928 0.55 100.64 Sarath &
6 1.0
100.339- 0.37- 98.96- Rao [8]
Sof NR NR
1003.391 0.98 100.15
98.80-
Vel 20-60 0.001 0.003 0.42
100.50 Uppalapati
8 1.0
99.30- & Parimi [9]
Sof 80-240 0.005 0.02 0.25
100.50
0.136- 100.36-
Vel 10-30 0.186 0.620
0.138 100.47 Proposed
5 1.0
0.020- 99.63- method
Sof 40-120 0.482 1.609
0.021 99.71
Vel – velpatasvir; Sof – sofosbuvir; NR – not reported.
ACKNOWLEDGMENT
Authors thank M/s Lara Drug Private Limited, Hyderabad (Telangana, India) for providing gift samples,
sofosbuvir and velpatasvir and also to CMR college of Pharmacy, Medchal for permitting to avail the
facilities for research work.
REFERENCES
1. J.P. Messina, I. Humphreys, A. Flaxman, A. Brown, G.S. Cooke, O.G. Pybus and E. Barnes,
Hepatology, 61(1), 77 (2015), DOI:10.1002/hep.27259.
2. J. S. Rani and N. Devanna, Rasayan J. Chem., 11(2), 452 (2018), DOI: 10.7324/RJC.2018.1122079.
3. C.W. Tseng, T.T. Chang, S.J. Tzeng, Y.H. Hsieh, T.H. Hung, H.T. Huang, S.F. Wu and K.C. Tseng,
Clin. Interv. Aging, 11, 327, (2016), DOI: 10.2147/CIA.S97242.
4. [Link]
5. J. Mamatha and N. Devanna, Rasayan J. Chem., 11(1), 392 (2018), DOI: 0.7324/RJC.2018.1111931.
6. Asselah T, Expert Opin. Pharmacother., 15(1), 121, (2014), DOI: 10.1517/14656566.2014.857656.
7. E. Mogalian, P. German, B.P. Kearney, C.Y. Yang, D. Brainard, J. Link, J. McNally, L. Han, J. Ling
and A. Mathias, Antimicrob. Agents. Chemother., 61(5), e02084-16, (2017), DOI:
10.1128/AAC.02084-16.
8. N. Sarath and J.V.L.N.S. Rao, World J. Pharm. Pharma. Sci., 6(9),1596(2017), DOI:
10.20959/wjpps20179-10099.
9. J. Uppalapati and U. Parimi, Indo American J. Pharma. Res., 7(8), 401 (2017).
10. Q1A (R2) International Conference on Harmonization (ICH) of technical requirements for the
registration of pharmaceutical for human use stability testing of new drugs substance and products,
(2003).
11. ICH Validation of analytical procedures; Text and methodology; Q2(R1), International Conference
on Harmonization, (2005).
[RJC-2010/2018]
1066
CONCURRENT ESTIMATION OF SOFOSBUVIR J. Saroja et al.